| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
CBP/p300
p300/CBP and BET bromodomains. NEO2734 binds to the bromodomains of BET proteins and the histone acetyltransferase paralogs CBP and p300, preventing the binding of BET proteins to acetylated histones. It has IC50 values of <30 nM for both targets. |
|---|---|
| ln Vitro |
NEO2734 (1 μM) causes G1 cell cycle arrest and differentiation [1]. In NMC cell lines, NEO2734 (1 μM) quickly causes squamous differentiation and produces keratin or involucrin, indicators of terminal squamous differentiation [1]. In vitro and in vivo, NEO2734 exhibits activity in PCa cells harboring hotspot mutations (F133V) and non-hotspot mutations (Q165P) [2].
NEO2734 has IC50 values of <30 nM for both p300/CBP and BET bromodomains. It is active in SPOP mutant and wild-type prostate cancer cells. In vitro, it inhibits the proliferation of various cancer cell lines with high potency. |
| ln Vivo |
In preclinical xenograft models, NEO2734 (5, 8, 10 mg/kg, oral) slows growth and increases survival [1].
NEO2734 is orally active and shows efficacy in mouse xenograft models. It is active in both SPOP mutant and wild-type prostate cancer models. In vivo, it suppresses tumor growth and has been cited in multiple high-impact journals for its anticancer activity. |
| Enzyme Assay |
In vitro enzyme assays for bromodomain binding are performed using AlphaScreen or TR-FRET technologies. Recombinant bromodomains and acetylated histone peptides are used. The compound's ability to displace a labeled probe is measured, and IC50 values are calculated.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: NUT carcinoma patient cell lines (TC-797 and PER-403). Tested Concentrations: 1 μM. Incubation Duration: 6 h. Experimental Results: Results in greater loss of MYC protein. Cells (e.g., prostate cancer cell lines) are treated with NEO2734, and cell viability is measured using CellTiter-Glo assays. Apoptosis is assessed by Annexin V/PI staining. Bromodomain inhibition is confirmed by Western blotting for downstream targets (e.g., c-Myc). Cell cycle analysis is performed by flow cytometry. |
| Animal Protocol |
Animal/Disease Models: Mice (PER-403 and 14169 models)[1].
Doses: 5, 8, 10 mg/kg Route of Administration: Orally, one time/day for 28 days. Experimental Results: Two of the three mice treated with NEO2734 were alive by day 100. Provided markedly improved survival compared with EP, i-BET-762, and even iBET-762+EP by day 100 following initiation of treatment. In vivo studies are conducted in mouse xenograft models using prostate cancer cell lines. NEO2734 is administered orally at various doses (e.g., 10, 30, 100 mg/kg). Tumor volume is measured by calipers. Tumors are harvested for histology and biomarker analysis. Body weight and clinical signs are monitored. |
| ADME/Pharmacokinetics |
NEO2734 is orally active. It has a molecular weight of 435.44 and is soluble in DMSO (87 mg/mL). It can be formulated for oral administration as a homogeneous suspension in CMC-Na (≥5 mg/mL). It is stored at -20°C.
|
| Toxicity/Toxicokinetics |
Detailed toxicological profiles of NEO2734 are not extensively reported. In vivo studies show that it is tolerated at efficacious doses. As a dual inhibitor of epigenetic regulators, it may have on-target toxicities. The compound is typically well-tolerated in animal models at therapeutic doses.
|
| References |
|
| Additional Infomation |
NEO2734 is a research-grade dual p300/CBP and BET bromodomain inhibitor. It is used in cancer research, particularly in prostate cancer. It is not approved for clinical use. Its molecular formula is C22H24F3N3O3 and its molecular weight is 435.44.
|
| Molecular Formula |
C22H24F3N3O3
|
|---|---|
| Molecular Weight |
435.439476013184
|
| Exact Mass |
435.176
|
| CAS # |
2081072-29-7
|
| PubChem CID |
126582741
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
733
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(OCCN1C2C=C(C3C=C(C)C(N(C)C=3)=O)C=CC=2N=C1C1CCOCC1)(F)F
|
| InChi Key |
KPWWFNXRLAAREN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H24F3N3O3/c1-14-11-17(13-27(2)21(14)29)16-3-4-18-19(12-16)28(7-10-31-22(23,24)25)20(26-18)15-5-8-30-9-6-15/h3-4,11-13,15H,5-10H2,1-2H3
|
| Chemical Name |
1,3-dimethyl-5-[2-(oxan-4-yl)-3-[2-(trifluoromethoxy)ethyl]benzimidazol-5-yl]pyridin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (229.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2965 mL | 11.4826 mL | 22.9653 mL | |
| 5 mM | 0.4593 mL | 2.2965 mL | 4.5931 mL | |
| 10 mM | 0.2297 mL | 1.1483 mL | 2.2965 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
